 Edward Gardner
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 49 | 2025 | 3154 | 3.620 |
Why?
| | Anti-HIV Agents | 24 | 2025 | 888 | 2.460 |
Why?
| | Antiretroviral Therapy, Highly Active | 8 | 2025 | 278 | 1.770 |
Why?
| | HIV Protease Inhibitors | 5 | 2019 | 69 | 1.480 |
Why?
| | HIV-1 | 13 | 2024 | 896 | 1.440 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 250 | 1.410 |
Why?
| | Viral Load | 12 | 2025 | 526 | 1.280 |
Why?
| | Medication Adherence | 9 | 2019 | 539 | 1.050 |
Why?
| | Drug Substitution | 2 | 2025 | 63 | 0.940 |
Why?
| | HIV Integrase Inhibitors | 3 | 2024 | 78 | 0.910 |
Why?
| | Drug Utilization Review | 1 | 2025 | 61 | 0.900 |
Why?
| | Continuity of Patient Care | 3 | 2021 | 291 | 0.860 |
Why?
| | Tenofovir | 10 | 2024 | 295 | 0.840 |
Why?
| | Adenine | 10 | 2024 | 339 | 0.790 |
Why?
| | Patient Compliance | 5 | 2017 | 588 | 0.740 |
Why?
| | Drug Resistance, Viral | 5 | 2011 | 122 | 0.730 |
Why?
| | Drug Monitoring | 6 | 2019 | 395 | 0.700 |
Why?
| | HIV | 5 | 2025 | 250 | 0.580 |
Why?
| | Darunavir | 1 | 2019 | 20 | 0.580 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.570 |
Why?
| | Organophosphates | 6 | 2020 | 187 | 0.550 |
Why?
| | Mass Screening | 7 | 2025 | 1347 | 0.540 |
Why?
| | Emtricitabine | 8 | 2019 | 205 | 0.540 |
Why?
| | Hepatitis C | 4 | 2025 | 254 | 0.510 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2310 | 0.500 |
Why?
| | Antiviral Agents | 5 | 2021 | 767 | 0.490 |
Why?
| | Middle Aged | 42 | 2025 | 35875 | 0.420 |
Why?
| | Healthcare Disparities | 1 | 2021 | 727 | 0.420 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 235 | 0.410 |
Why?
| | Health Services Administration | 1 | 2013 | 8 | 0.410 |
Why?
| | Male | 54 | 2025 | 72315 | 0.400 |
Why?
| | Alanine | 3 | 2024 | 171 | 0.400 |
Why?
| | Adult | 48 | 2025 | 40449 | 0.400 |
Why?
| | Hepacivirus | 4 | 2025 | 243 | 0.390 |
Why?
| | Humans | 70 | 2025 | 144759 | 0.380 |
Why?
| | Public Health Administration | 1 | 2013 | 73 | 0.380 |
Why?
| | Female | 53 | 2025 | 78271 | 0.370 |
Why?
| | Sustained Virologic Response | 2 | 2025 | 46 | 0.370 |
Why?
| | Pneumococcal Infections | 2 | 2024 | 103 | 0.360 |
Why?
| | RNA, Viral | 5 | 2025 | 688 | 0.360 |
Why?
| | Pyrrolidinones | 1 | 2011 | 29 | 0.350 |
Why?
| | CD4 Lymphocyte Count | 7 | 2019 | 277 | 0.350 |
Why?
| | Drug Therapy, Combination | 7 | 2021 | 1047 | 0.340 |
Why?
| | Streptococcus pneumoniae | 2 | 2024 | 177 | 0.340 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2008 | 87 | 0.330 |
Why?
| | Antibodies, Neutralizing | 3 | 2025 | 340 | 0.320 |
Why?
| | Fees and Charges | 1 | 2010 | 11 | 0.320 |
Why?
| | Current Procedural Terminology | 1 | 2010 | 19 | 0.320 |
Why?
| | Pyridones | 2 | 2024 | 199 | 0.310 |
Why?
| | Patient Education as Topic | 3 | 2016 | 780 | 0.310 |
Why?
| | Online Systems | 1 | 2009 | 21 | 0.310 |
Why?
| | Dried Blood Spot Testing | 4 | 2019 | 126 | 0.310 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2010 | 80 | 0.300 |
Why?
| | Fibromyalgia | 1 | 2009 | 51 | 0.290 |
Why?
| | Delivery of Health Care | 3 | 2014 | 947 | 0.290 |
Why?
| | Drug Overdose | 3 | 2019 | 370 | 0.280 |
Why?
| | Rheumatology | 1 | 2010 | 133 | 0.280 |
Why?
| | Clostridium butyricum | 1 | 2008 | 2 | 0.280 |
Why?
| | Organophosphonates | 3 | 2015 | 97 | 0.280 |
Why?
| | Deoxycytidine | 3 | 2015 | 221 | 0.260 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 634 | 0.260 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2009 | 239 | 0.250 |
Why?
| | Clostridium Infections | 1 | 2008 | 74 | 0.250 |
Why?
| | Naloxone | 3 | 2018 | 132 | 0.250 |
Why?
| | Retrospective Studies | 12 | 2025 | 17066 | 0.250 |
Why?
| | Prospective Studies | 13 | 2025 | 7990 | 0.230 |
Why?
| | Treatment Outcome | 11 | 2025 | 11679 | 0.230 |
Why?
| | Narcotic Antagonists | 3 | 2018 | 205 | 0.230 |
Why?
| | Urban Health Services | 1 | 2025 | 70 | 0.230 |
Why?
| | Kartagener Syndrome | 1 | 2005 | 31 | 0.230 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 73 | 0.230 |
Why?
| | Immunization, Passive | 1 | 2025 | 87 | 0.220 |
Why?
| | Health Care Costs | 2 | 2011 | 427 | 0.220 |
Why?
| | Macrolides | 1 | 2005 | 69 | 0.220 |
Why?
| | Lymphocyte Activation | 3 | 2021 | 1126 | 0.220 |
Why?
| | Analgesics, Opioid | 4 | 2019 | 1143 | 0.220 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2005 | 81 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 985 | 0.220 |
Why?
| | Blood Chemical Analysis | 3 | 2014 | 109 | 0.220 |
Why?
| | Anus Neoplasms | 1 | 2025 | 32 | 0.220 |
Why?
| | Lymphopenia | 1 | 2025 | 65 | 0.220 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2005 | 63 | 0.210 |
Why?
| | Nasopharynx | 1 | 2024 | 73 | 0.210 |
Why?
| | Time Factors | 5 | 2025 | 7173 | 0.210 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 86 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 1 | 2011 | 885 | 0.210 |
Why?
| | Pre-Exposure Prophylaxis | 3 | 2017 | 246 | 0.200 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 397 | 0.200 |
Why?
| | Desiccation | 2 | 2014 | 24 | 0.200 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 18 | 0.200 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 197 | 0.200 |
Why?
| | Cohort Studies | 6 | 2025 | 5960 | 0.190 |
Why?
| | Specimen Handling | 2 | 2014 | 186 | 0.180 |
Why?
| | Quality of Life | 3 | 2025 | 3185 | 0.170 |
Why?
| | Sepsis | 1 | 2008 | 640 | 0.170 |
Why?
| | Vaccines, Conjugate | 1 | 2021 | 60 | 0.170 |
Why?
| | Viremia | 2 | 2019 | 158 | 0.170 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1169 | 0.160 |
Why?
| | Weight Gain | 1 | 2024 | 556 | 0.160 |
Why?
| | Research Subjects | 1 | 2020 | 41 | 0.160 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2021 | 130 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 130 | 0.160 |
Why?
| | Substance-Related Disorders | 2 | 2018 | 1094 | 0.160 |
Why?
| | Adaptive Immunity | 1 | 2021 | 169 | 0.150 |
Why?
| | Gender Identity | 1 | 2020 | 121 | 0.150 |
Why?
| | Internship and Residency | 1 | 2010 | 1257 | 0.150 |
Why?
| | Time-to-Treatment | 1 | 2021 | 243 | 0.150 |
Why?
| | Oxazines | 1 | 2019 | 37 | 0.140 |
Why?
| | Sexual and Gender Minorities | 2 | 2020 | 251 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 3 | 2016 | 573 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2025 | 1720 | 0.140 |
Why?
| | Colorado | 5 | 2018 | 4564 | 0.140 |
Why?
| | Rectum | 2 | 2016 | 180 | 0.140 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 15 | 0.130 |
Why?
| | Atazanavir Sulfate | 2 | 2015 | 42 | 0.130 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 779 | 0.130 |
Why?
| | Terminology as Topic | 1 | 2019 | 255 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 781 | 0.120 |
Why?
| | B-Lymphocytes | 2 | 2021 | 876 | 0.120 |
Why?
| | Homosexuality, Male | 2 | 2016 | 222 | 0.120 |
Why?
| | Genitalia | 1 | 2016 | 34 | 0.120 |
Why?
| | Piperazines | 1 | 2019 | 381 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2017 | 254 | 0.110 |
Why?
| | Chronic Pain | 2 | 2018 | 290 | 0.110 |
Why?
| | Genitalia, Female | 1 | 2015 | 42 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 851 | 0.110 |
Why?
| | Coinfection | 1 | 2016 | 141 | 0.110 |
Why?
| | Disease Transmission, Infectious | 1 | 2014 | 69 | 0.100 |
Why?
| | Mental Health Services | 1 | 2019 | 473 | 0.100 |
Why?
| | Young Adult | 10 | 2024 | 14105 | 0.100 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 20 | 0.100 |
Why?
| | Biomarkers | 6 | 2021 | 4271 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 255 | 0.090 |
Why?
| | Equivalence Trials as Topic | 2 | 2023 | 36 | 0.090 |
Why?
| | Aged | 9 | 2025 | 25913 | 0.090 |
Why?
| | Risk Factors | 5 | 2025 | 10779 | 0.090 |
Why?
| | Vaccination | 1 | 2021 | 1423 | 0.090 |
Why?
| | Genotype | 2 | 2025 | 1833 | 0.090 |
Why?
| | Zidovudine | 1 | 2012 | 77 | 0.090 |
Why?
| | Lamivudine | 1 | 2012 | 65 | 0.090 |
Why?
| | United States | 4 | 2024 | 15966 | 0.080 |
Why?
| | Intention to Treat Analysis | 2 | 2021 | 80 | 0.080 |
Why?
| | Population Surveillance | 1 | 2014 | 485 | 0.080 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2010 | 14 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1168 | 0.080 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 45 | 0.080 |
Why?
| | Treatment Failure | 2 | 2021 | 365 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1982 | 0.080 |
Why?
| | Chromatography, Liquid | 3 | 2019 | 454 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1326 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2021 | 3604 | 0.080 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 102 | 0.080 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2009 | 93 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 576 | 0.070 |
Why?
| | Adolescent | 8 | 2021 | 22428 | 0.070 |
Why?
| | Public Health | 1 | 2013 | 566 | 0.070 |
Why?
| | Hospitalization | 3 | 2025 | 2433 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1414 | 0.070 |
Why?
| | Oligopeptides | 1 | 2009 | 269 | 0.070 |
Why?
| | Comprehension | 1 | 2009 | 180 | 0.070 |
Why?
| | Cost Savings | 1 | 2008 | 86 | 0.070 |
Why?
| | Educational Status | 1 | 2009 | 467 | 0.060 |
Why?
| | Disease Progression | 2 | 2023 | 2847 | 0.060 |
Why?
| | Drug Costs | 1 | 2008 | 116 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2021 | 2029 | 0.060 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 128 | 0.060 |
Why?
| | Catheterization, Central Venous | 1 | 2008 | 122 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1907 | 0.060 |
Why?
| | Osteomyelitis | 1 | 2008 | 143 | 0.060 |
Why?
| | Axonemal Dyneins | 1 | 2005 | 8 | 0.060 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2005 | 26 | 0.060 |
Why?
| | Dyneins | 1 | 2005 | 35 | 0.060 |
Why?
| | Pyridines | 1 | 2009 | 605 | 0.060 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 95 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1306 | 0.050 |
Why?
| | Inflammation | 1 | 2016 | 2878 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2005 | 88 | 0.050 |
Why?
| | Genetic Linkage | 1 | 2005 | 273 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2025 | 164 | 0.050 |
Why?
| | Half-Life | 2 | 2016 | 151 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2005 | 138 | 0.050 |
Why?
| | Oropharynx | 1 | 2024 | 46 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2005 | 112 | 0.050 |
Why?
| | Gene Expression | 1 | 2009 | 1490 | 0.050 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.050 |
Why?
| | Bronchiectasis | 1 | 2005 | 112 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2025 | 1173 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2010 | 780 | 0.050 |
Why?
| | Pilot Projects | 1 | 2009 | 1886 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2008 | 388 | 0.050 |
Why?
| | Spleen | 1 | 2005 | 508 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1985 | 0.050 |
Why?
| | Curriculum | 1 | 2010 | 1059 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1539 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.050 |
Why?
| | Logistic Models | 1 | 2008 | 2117 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3671 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 558 | 0.050 |
Why?
| | Primary Health Care | 3 | 2018 | 1733 | 0.040 |
Why?
| | Recurrence | 1 | 2005 | 1135 | 0.040 |
Why?
| | Medical Futility | 1 | 2021 | 31 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2022 | 133 | 0.040 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 10 | 0.040 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 36 | 0.040 |
Why?
| | Ultrasonography | 1 | 2005 | 770 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2025 | 672 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2021 | 182 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 366 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2025 | 2925 | 0.040 |
Why?
| | Transsexualism | 1 | 2020 | 15 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 405 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2021 | 148 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 4089 | 0.040 |
Why?
| | Plasma | 2 | 2012 | 225 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 138 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2019 | 93 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 1075 | 0.040 |
Why?
| | Qualitative Research | 2 | 2016 | 1671 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5408 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2019 | 147 | 0.030 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 1185 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1519 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2006 | 1098 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 322 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 12 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2947 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1887 | 0.030 |
Why?
| | Cell Communication | 1 | 2018 | 324 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 535 | 0.030 |
Why?
| | Ribavirin | 1 | 2016 | 80 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 109 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 601 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 780 | 0.030 |
Why?
| | Blood | 1 | 2015 | 109 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2730 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 836 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1658 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2016 | 152 | 0.030 |
Why?
| | Risk | 1 | 2016 | 911 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5868 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2115 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 681 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2015 | 284 | 0.020 |
Why?
| | Physicians, Primary Care | 1 | 2015 | 207 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 415 | 0.020 |
Why?
| | Mental Health | 1 | 2019 | 790 | 0.020 |
Why?
| | Focus Groups | 1 | 2015 | 573 | 0.020 |
Why?
| | Dideoxynucleotides | 1 | 2012 | 16 | 0.020 |
Why?
| | Cytidine Triphosphate | 1 | 2012 | 19 | 0.020 |
Why?
| | Thymine Nucleotides | 1 | 2012 | 19 | 0.020 |
Why?
| | Self Report | 1 | 2016 | 872 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 11 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3409 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 90 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1125 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2010 | 266 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 140 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2010 | 307 | 0.020 |
Why?
| | Prednisone | 1 | 2010 | 221 | 0.020 |
Why?
| | Drug Interactions | 1 | 2010 | 398 | 0.020 |
Why?
| | Ritonavir | 1 | 2009 | 75 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4282 | 0.020 |
Why?
| | Doxorubicin | 1 | 2010 | 397 | 0.020 |
Why?
| | Haplotypes | 1 | 2009 | 490 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 1244 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 612 | 0.020 |
Why?
| | Erythrocytes | 1 | 2012 | 757 | 0.020 |
Why?
| | Animals | 1 | 2009 | 38058 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 824 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 2112 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8265 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2930 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6048 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1953 | 0.010 |
Why?
|
|
Gardner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|